Article
KRAS withdrawal in Cholangiocarcinoma leads to immune infiltration and tumor regression
2025-06-17
Abstract excerpt
<h4>Background and Aims</h4> Cholangiocarcinoma (CCA) is a liver cancer with poor survival rates. Current treatments, including targeted therapies for specific mutations, are limited and benefit only a small subset of patients. KRAS mutations are found in 15-40% of CCA, representing a new potential treatment target. Whether KRAS inhibition leads to CCA tumor regression is unknown partly due to the lack of condit...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 961c23b5-bccf-5e4b-a2b2-acb024f472d4
- DOI
- 10.1101/2025.06.11.659210
